{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:06:53Z","timestamp":1781140013818,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the clinical and radiological outcomes and glucocorticoid\u2010sparing effect of rituximab therapy in 13 patients with retroperitoneal fibrosis (RPF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed the data of both glucocorticoid\u2010naive and glucocorticoid\u2010resistant RPF patients who were treated with rituximab. Demographic features, positron emission tomography computed tomography (PET\u2010CT) findings, and clinical and histopathologic outcomes were collected retrospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We evaluated the data of 13 RPF patients (8M\/5F). The median follow\u2010up duration was 28\u2009months (interquartile range [IQR] 24.5\u201355.5\u2009months) and median age at the time of diagnosis was 50.8\u2009years (IQR 46.5\u201354.5\u2009years). PET\u2010CT scans showed that following the rituximab therapy, the craniocaudal diameter of the RPF mass reduced from 74\u2009mm (IQR 50.5\u2013130\u2009mm) to 52\u2009mm (IQR 35\u201377\u2009mm; <jats:italic>p<\/jats:italic>\u2009=\u2009.06), and periaortic thickness of the RPF mass reduced from 14\u2009mm (5.5\u201321.9\u2009mm) to 7\u2009mm (4.5\u201311\u2009mm; <jats:italic>p<\/jats:italic>\u2009=\u2009.12). The maximum standardized uptake value (based on body weight) of the RPF mass decreased from 5.8 (4.3\u20139.7) to 3.1 (2.8\u20135.3) after the therapy (<jats:italic>p<\/jats:italic>\u2009=\u2009.03). The number of patients with hydronephrosis reduced from 11 to 6 following rituximab therapy (<jats:italic>p<\/jats:italic>\u2009=\u2009.04). Before rituximab, nine patients received a median dose of 10\u2009mg (IQR 0\u201327.5\u2009mg) prednisolone per day. After the rituximab treatment, we discontinued prednisolone treatment for four out of nine patients and reduced the daily dose for the remaining patients. At the time of the final evaluation of the patients, the median prescribed prednisolone dose was 5\u2009mg\/day (IQR 2.5\u20137.5\u2009mg\/day; <jats:italic>p<\/jats:italic>\u2009=\u2009.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study shows that rituximab may be a favorable treatment option for glucocorticoid\u2010refractory RPF patients with high disease activity on PET\u2010CT scans.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14798","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:04:06Z","timestamp":1687784646000},"page":"1714-1721","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rituximab in the management of retroperitoneal fibrosis: A\u00a0single tertiary rheumatology care center experience"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-1374","authenticated-orcid":false,"given":"Mert","family":"Oztas","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-9017","authenticated-orcid":false,"given":"Izzet","family":"Altun","sequence":"additional","affiliation":[{"name":"Department of Medicine St. Agnes Medical Center  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-7992","authenticated-orcid":false,"given":"Ali Yagiz","family":"Ayla","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Cerme","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-9155","authenticated-orcid":false,"given":"Cetin","family":"Demirdag","sequence":"additional","affiliation":[{"name":"Department of Urology Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-9331","authenticated-orcid":false,"given":"Sertac","family":"Asa","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-5184","authenticated-orcid":false,"given":"Kerim","family":"Sonmezoglu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-2282","authenticated-orcid":false,"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Cerrahpasa Medical Faculty, Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480200900510"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(03)00056-1"},{"issue":"3","key":"e_1_2_11_4_1","first-page":"250","article-title":"The clinical significance of retroperitoneal fibrosis","volume":"81","author":"Koep L","year":"1977","journal-title":"Surgery"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh326"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.172.1.2740497"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa083"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.02.268"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60934-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.14712\/23362936.2016.3"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel417"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200148"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203267"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216258"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-00140-9"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.108530"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21074"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2144-6"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.02.008"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.10.046"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T08:46:20Z","timestamp":1693817180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/1756-185X.14798"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14798","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"2022-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}